Fewer precancerous lesions are being found in young women undergoing cervical cancer screenings thanks to the human papillomavirus (HPV) vaccine. Rates of precancerous lesions in women between the ages of 20 and 24 dropped by roughly 80 percent from 2008 to 2022,

Because almost all cases of cervical cancer can be traced to HPV, some countries think the vaccine will help them eliminate the disease within years.

The human papillomavirus (HPV) vaccine is having a huge impact on cervical cancer prevention among young women, a U.S. government report published Thursday suggests. Why it matters: The CDC report shows that rates of precancerous lesions among women aged 20-24 screened for cervical cancer dropped by about 80% from 2008 to 2022.

Cervical precancer rates dropped precipitously among young women who underwent screening after the human papillomavirus (HPV) vaccine was first recommended in the U.S., CDC researchers reported. Among women ages 20 to 24 who were screened for cervical cancer from 2008 to 2022,